Major Allergy Relief delivers 4mg chlorpheniramine maleate per tablet, a first-generation H1-receptor antagonist providing broad-spectrum histamine blockade for allergic rhinitis and upper respiratory symptomatology. The formulation effectively suppresses allergic cascade manifestations including rhinorrhea, sternutatory episodes, ocular pruritus, and pharyngeal irritation associated with seasonal environmental allergens and viral respiratory infections. The standard-strength dosing aligns with established therapeutic protocols for acute allergy symptom management across adult populations. The small tablet format facilitates convenient oral administration without requiring water or specialized preparation, optimizing medication adherence during acute symptom episodes. The 24-tablet supply provides 24-day treatment duration at single daily dosing or 12-day coverage with twice-daily administration, supporting flexible symptom management across varied allergy severity presentations. The portable packaging accommodates travel and emergency access, ensuring consistent antihistamine availability during seasonal allergy exacerbations or unexpected respiratory symptom onset. This cost-effective formulation represents a practical first-line therapeutic option for individuals requiring reliable allergy symptom control without prescription requirements or complex dosing regimens.